Ricks强调选择性胰淀素受体激动剂lintide是礼来史上最大的三期项目，二期减重19%且胃肠副作用很低。
这是我们投入过的最大的三期项目，药物名为lintide，是一种高选择性胰淀素受体激动剂，是一种治疗肥胖的新机制，与GLP-1类似。原文 (en)
It's large program actually the largest phase 3 program we've ever invested in with a drug called lintide. This is a highly selective amalin receptor agonist. A new mechanism to treat obesity similar to GLP-1.
Ricks认为AI蛋白质结构预测只解决了药物发现中约千分之一的问题，对AI药物发现的炒作持保留态度。
机器可以“相当好地预测一些事情，比如预测蛋白质结构”，但“这只是我们在药物发现中面临的问题的千分之一左右”。原文 (en)
A machine can “predict things pretty well, like predicting the structure of a protein,” Ricks said according to Fortune, “but that is one maybe 1,000th of the kind of problems we face in drug discovery.”
Ricks称语言模型因以人类语言训练而不擅长生物和化学，更倾向于使用多个针对具体预测问题的窄模型。
语言模型在生物和化学方面“并不特别擅长”，因为“它们是用人类语言训练的，而不是用化学、物理和生物的语言”。原文 (en)
language models are “not particularly good” at biology and chemistry because “they’re trained on the human language, not on the language of chemistry, physics, and biology.”
Ricks 表示现在是合并礼来美国与国际商业部门、巩固发展势头的合适时机，并任命曾执掌这两块业务的 Ilya Yuffa 领导全球面向客户的运营。
为了巩固我们的发展势头，现在正是整合各地区业务、以产生更大影响力的合适时机。Ilya 既管理过我们的国际业务，也管理过美国业务，他丰富的经验和对卓越的追求使他格外适合领导我们全球面向客户的运营。原文 (en)
To build on our momentum, now is the right time to consolidate our geographies for greater impact. Ilya has run both our international and U.S. businesses, and his range of experience and commitment to excellence make him uniquely qualified to lead our customer-facing operations worldwide.
David Ricks 称美国仅有 3% 至 10% 的潜在患者接受减重治疗，市场扩张空间巨大。
礼来负责人 David Ricks 在接受 CNBC 采访时表示，美国只有 3% 至 10% 的潜在患者获得减重治疗，并补充说“这个市场的扩张空间非常巨大”。原文 (en)
Lilly chief David Ricks, in a CNBC interview, said that only 3% to 10% of potential patients access weight loss care in the U.S., and he added that "room for expansion here of this market is dramatic."
David Ricks称美国仅有3%至10%的潜在患者获得减重治疗，市场扩张空间巨大。
在美国，只有3%到10%的潜在患者能获得减重治疗，他补充说，该市场的扩张空间十分巨大。原文 (en)
only 3% to 10% of potential patients access weight loss care in the U.S., and he added that "room for expansion here of this market is dramatic."